首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1757888

子宮肌瘤治療設備的全球市場

Uterine Fibroid Treatment Devices

出版日期: 2025年06月27日 | 出版商:

Global Industry Analysts, Inc. | 英文 276 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年全球子宮肌瘤治療設備市場規模將達 81 億美元

全球子宮肌瘤治療設備市場規模預計在2024年為53億美元，預計2030年將達到81億美元，2024年至2030年的複合年成長率為7.4%。外科手術是本報告分析的細分市場之一，預計其複合年成長率為8.7%，到分析期結束時規模將達到53億美元。消融細分市場在分析期間內的複合年成長率預計為5.1%。

美國市場規模估計為 14 億美元，中國市場預計複合年成長率為 11.8%

美國子宮肌瘤治療設備市場規模預計2024年達到14億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到17億美元，在2024-2030年的分析期間內，複合年成長率為11.8%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為3.6%和7.2%。在歐洲，預計德國市場的複合年成長率為4.9%。

全球「子宮肌瘤治療設備」市場—主要趨勢與促進因素摘要

為什麼晚期子宮肌瘤治療的需求越來越大？

子宮肌瘤是一種子宮良性腫瘤，其全球負擔正在顯著增加，影響到 50 歲左右的 70-80% 的女性，有症狀的病例會導致大量出血、骨盆疼痛、不孕和其他併發症。這種日益成長的盛行率直接影響了對有效、微創治療方法的需求，特別是對於尋求保宮手術的育齡婦女。雖然子宮切除術歷來是治療的主要方法，但患者越來越偏好保宮手術，如肌瘤摘除、子宮動脈栓塞術 (UAE)，以及微創手術，如腹腔鏡和機器人輔助手術。子宮切除術的恥辱感和社會影響正在加劇這種轉變，特別是在高度重視生育能力的文化中。此外，生活方式的改變、妊娠晚期和肥胖已被確定為風險增加因素，從而導致早期診斷和治療。醫療保健產業對女性健康的關注度不斷提高，加上由於宣傳宣傳活動加強而導致的篩檢和診斷率激增，進一步推動了子宮肌瘤治療設備市場的發展。

科技和創新如何重新定義治療方法？

創新突破是子宮肌瘤治療發展的核心，醫療設備製造商不斷推出尖端設備，旨在改善臨床療效、縮短恢復期並減少手術併發症。高強度聚焦超音波(HIFU)、射頻消融 (RFA) 和磁振造影導引聚焦超音波手術 (MRgFUS) 等治療技術正在重新定義非侵入性或微創治療方法。這些設備能夠精準靶向子宮肌瘤，且不會傷害周圍組織，從而為患者提供快速緩解、更少副作用和門診病人便利的治療體驗。此外，腹腔鏡電動粉碎器和先進的子宮鏡器械也正在不斷改進，以提高安全性，尤其是考慮到過去對組織種植的擔憂。機器人手術系統雖然價格昂貴，但擴大被三級醫院採用，以提高複雜子宮肌瘤切除術的準確性。這些技術進步不僅增強了醫生的信心，也為基層醫院和門診診所提供了治療的可能性，使優質醫療服務的可近性更加民主化。

醫療保健系統和提供者正在採取哪些措施來擴大醫療服務覆蓋範圍？

政策措施、保險覆蓋改革和臨床指引的不斷演變，共同影響子宮肌瘤治療的可近性。在高所得國家，微創門診治療的普及性降低了治療成本，也讓治療更方便。許多政府和私人醫療機構現已將子宮肌瘤治療列為女性基本醫療保健的一部分，從而改善了診斷、轉診和津貼流程。同時，中低收入國家 (LMIC) 正在加大對行動診斷單元、婦科醫生培訓計畫以及旨在意識提升的公共衛生宣傳活動的投資。跨國非政府組織和全球衛生組織也透過資助醫療任務和向農村醫院捐贈設備，為能力建設做出貢獻。此外，醫院正在整合多學科子宮肌瘤診所，將婦科、放射科和疼痛管理相結合，提供整體護理，確保患者獲得正確的實證治療。向門診治療和當日出院通訊協定的轉變也在最佳化醫院資源並減輕病患負擔。

是什麼推動了子宮肌瘤治療設備市場的快速成長？

子宮肌瘤治療設備市場的成長受到多種因素的驅動，這些因素與技術進步、臨床實踐和患者偏好密切相關。非侵入性和微創設備的廣泛使用極大地改變了傳統開放性手術的治療模式，越來越多的患者尋求早期康復和保留生育能力。經陰道超音波和核磁共振等影像技術的改進導致診斷病例的增加，也推動了手術數量的成長。隨著對子宮肌瘤認知的提高，女性正在積極尋求早期療育和子宮切除手術的替代方案。此外，由於基於設備的子宮肌瘤治療具有操作效率高且成本效益比佳的特點，私人和公共醫療保健提供者正在加大對此類治療的投資。門診和流動手術中心的不斷成長，尤其是在北美和亞太部分地區，正在擴大新型治療設備的商業性潛力。醫療支出的增加、生育延遲等人口結構變化以及肥胖和荷爾蒙失調發病率的上升進一步推動了需求。這些因素共同為未來幾年的持續市場擴張奠定了堅實而多面向的基礎。

部分

科技（手術、消融）、治療方式（侵入性、微創、非侵入性）

調查企業範例（共42家企業）

AbbVie Inc.
Boston Scientific Corporation
CONMED Corporation
CooperSurgical Inc.
Ethicon, Inc.
Gynesonics
Hologic, Inc.
INSIGHTEC Ltd.
Karl Storz SE & Co. KG
Lumenis Be Ltd.
Medtronic plc
Merit Medical Systems, Inc.
Minerva Surgical, Inc.
Myovant Sciences GmbH
ObsEva SA
Olympus Corporation
Philips Healthcare
Profound Medical Corp.
Siemens Healthineers AG
Stryker Corporation

人工智慧整合

我們正在利用可操作的專家內容和人工智慧工具來改變市場和競爭情報。

Global 特定產業SLM 的典型規範，而是建立了一個從全球專家收集的內容庫，其中包括視訊錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口狀況（成品和原始OEM）預測其競爭態勢的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括銷貨成本成本 (COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

The global market for Uterine Fibroid Treatment Devices estimated at US$5.3 Billion in the year 2024, is expected to reach US$8.1 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2024-2030. Surgical, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth in the Ablation segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 11.8% CAGR

The Uterine Fibroid Treatment Devices market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 11.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global "Uterine Fibroid Treatment Devices" Market - Key Trends & Drivers Summarized

Why Is There a Rising Demand for Advanced Uterine Fibroid Treatments?

The global burden of uterine fibroids-benign tumors of the uterus-has grown substantially, affecting up to 70-80% of women by the age of 50, with symptomatic cases leading to heavy bleeding, pelvic pain, infertility, and other complications. This rising incidence is directly influencing the demand for effective, less invasive treatment modalities, particularly in reproductive-age women who seek uterine-sparing procedures. Historically, hysterectomy was the dominant treatment; however, patient preference is increasingly shifting toward uterus-preserving alternatives such as myomectomy, uterine artery embolization (UAE), and minimally invasive surgeries like laparoscopic and robotic-assisted interventions. The stigma and social implications of undergoing hysterectomy-especially in cultures where fertility is highly valued-are reinforcing this transition. In addition, lifestyle changes, late pregnancies, and obesity have been identified as risk-enhancing factors, leading to earlier diagnosis and treatment. The healthcare industry’s increased focus on women’s health and a surge in screening and diagnostic rates, due in part to better awareness campaigns, are further propelling the market for uterine fibroid treatment devices.

How Are Technology and Innovation Redefining Treatment Modalities?

Innovative breakthroughs are at the heart of the evolution in uterine fibroid management, with medical device manufacturers introducing cutting-edge equipment designed to improve clinical outcomes, shorten recovery periods, and reduce surgical complications. Technologies such as high-intensity focused ultrasound (HIFU), radiofrequency ablation (RFA), and MRI-guided focused ultrasound surgery (MRgFUS) are redefining non-invasive or minimally invasive treatment approaches. These devices enable precise targeting of fibroids without damaging surrounding tissues, offering patients rapid relief with fewer side effects and outpatient-level convenience. Additionally, laparoscopic power morcellators and advanced hysteroscopic tools are being refined to improve safety, especially in light of past concerns around tissue dissemination. Robotic surgical systems, though expensive, are increasingly employed in tertiary care hospitals to improve accuracy in complex fibroid removal. These technological advancements are not only increasing physician confidence but are also expanding treatment availability to lower-tier hospitals and outpatient clinics, democratizing access to quality care.

What Are Healthcare Systems and Providers Doing to Expand Access?

Access to fibroid treatment is being shaped by a combination of policy efforts, insurance coverage reforms, and evolving clinical guidelines. In high-income countries, broader insurance inclusion of less invasive and outpatient procedures has helped bring down costs and improve uptake. Many governments and private providers are now classifying uterine fibroid treatments as part of essential women’s healthcare, leading to better diagnosis, referral, and subsidization processes. At the same time, low- and middle-income countries (LMICs) are catching up, with investments in mobile diagnostic units, training programs for gynecologic surgeons, and public health campaigns aimed at raising awareness. Multinational NGOs and global health organizations are also contributing to capacity building by funding medical missions and donating devices to rural hospitals. Furthermore, hospitals are integrating multidisciplinary fibroid clinics combining gynecology, radiology, and pain management to offer holistic care, ensuring that patients receive tailored, evidence-based treatment options. The shift toward outpatient care and same-day discharge protocols is also optimizing hospital resources and reducing patient burden.

What’s Driving the Escalating Growth in the Uterine Fibroid Treatment Devices Market?

The growth in the uterine fibroid treatment devices market is driven by several factors closely linked to technology evolution, clinical practices, and patient preferences. The widespread availability of non-invasive and minimally invasive devices is dramatically shifting treatment patterns away from traditional open surgery, attracting a larger volume of patients seeking faster recovery and fertility preservation. The expanding pool of diagnosed cases-due to improved imaging techniques like transvaginal ultrasound and MRI-is also increasing procedural volumes. Patient behavior is playing a pivotal role; as awareness about fibroids rises, women are actively seeking early intervention and alternatives to hysterectomy. Additionally, private and public healthcare providers are increasingly investing in device-based fibroid treatments due to their procedural efficiency and favorable cost-benefit ratios. The increasing presence of outpatient and ambulatory surgery centers, particularly in North America and parts of Asia-Pacific, is expanding the commercial viability of newer treatment devices. Rising healthcare spending, demographic shifts such as delayed childbirth, and higher incidences of obesity and hormonal disorders are further fueling demand. Together, these factors form a robust and multifaceted foundation for sustained market expansion in the years ahead.

SCOPE OF STUDY:

The report analyzes the Uterine Fibroid Treatment Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Surgical, Ablation); Mode of Treatment (Invasive, Minimally Invasive, Non-Invasive)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AbbVie Inc.
Boston Scientific Corporation
CONMED Corporation
CooperSurgical Inc.
Ethicon, Inc.
Gynesonics
Hologic, Inc.
INSIGHTEC Ltd.
Karl Storz SE & Co. KG
Lumenis Be Ltd.
Medtronic plc
Merit Medical Systems, Inc.
Minerva Surgical, Inc.
Myovant Sciences GmbH
ObsEva SA
Olympus Corporation
Philips Healthcare
Profound Medical Corp.
Siemens Healthineers AG
Stryker Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Tariff Impact on Global Supply Chain Patterns
- Uterine Fibroid Treatment Devices - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Rising Prevalence of Uterine Fibroids Drives Demand for Minimally Invasive Treatment Devices
- Patient Shift Toward Outpatient and Daycare Procedures Spurs Adoption of Non-Invasive Technologies
- Innovation in MRI-Guided and Ultrasound-Based Devices Expands Addressable Patient Pool
- Increasing Awareness Among Women Throws the Spotlight on Early Diagnosis and Treatment
- Favorable Reimbursement Policies Strengthen Business Case for Advanced Device Adoption
- Aging Population and Rising Obesity Rates Accelerate Demand for Fibroid Treatments
- Integration of AI and Robotics in Surgical Devices Generates Clinical Efficiency Opportunities
- Expansion of Women's Health Clinics in Emerging Markets Sustains Market Penetration
- Preference for Uterus-Preserving Treatments Drives Demand for Focused Ultrasound Systems
- Shorter Recovery Times and Lower Complication Risks Boost Adoption Across Age Groups
- Lack of Access and Cultural Barriers in Rural Areas Pose Distribution and Awareness Challenges
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Uterine Fibroid Treatment Devices Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Uterine Fibroid Treatment Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for Uterine Fibroid Treatment Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Surgical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Surgical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 7: World 15-Year Perspective for Surgical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Ablation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Invasive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Invasive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Invasive by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Minimally Invasive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Minimally Invasive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Minimally Invasive by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Non-Invasive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Non-Invasive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 19: World 15-Year Perspective for Non-Invasive by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 20: USA Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 21: USA Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 22: USA 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 23: USA Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 24: USA Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 25: USA 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
CANADA
- TABLE 26: Canada Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 27: Canada Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 28: Canada 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 29: Canada Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 30: Canada Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 31: Canada 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
JAPAN
- Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 32: Japan Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: Japan Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 34: Japan 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 35: Japan Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: Japan Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 37: Japan 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
CHINA
- Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 38: China Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: China Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 40: China 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 41: China Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: China Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 43: China 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
EUROPE
- Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 44: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 45: Europe Historic Review for Uterine Fibroid Treatment Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 46: Europe 15-Year Perspective for Uterine Fibroid Treatment Devices by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 47: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: Europe Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 49: Europe 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 50: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: Europe Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 52: Europe 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
FRANCE
- Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 53: France Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: France Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 55: France 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 56: France Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: France Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 58: France 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
GERMANY
- Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 59: Germany Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: Germany Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 61: Germany 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 62: Germany Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: Germany Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 64: Germany 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
ITALY
- TABLE 65: Italy Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: Italy Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 67: Italy 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 68: Italy Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: Italy Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 70: Italy 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
UNITED KINGDOM
- Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 71: UK Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: UK Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 73: UK 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 74: UK Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: UK Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 76: UK 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
SPAIN
- TABLE 77: Spain Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 78: Spain Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 79: Spain 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 80: Spain Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: Spain Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 82: Spain 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
RUSSIA
- TABLE 83: Russia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: Russia Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 85: Russia 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 86: Russia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Russia Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 88: Russia 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
REST OF EUROPE
- TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: Rest of Europe Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 91: Rest of Europe 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Rest of Europe Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 94: Rest of Europe 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
ASIA-PACIFIC
- Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 96: Asia-Pacific Historic Review for Uterine Fibroid Treatment Devices by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 97: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Devices by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
- TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Asia-Pacific Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 100: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: Asia-Pacific Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 103: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
AUSTRALIA
- Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 104: Australia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: Australia Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 106: Australia 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 107: Australia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: Australia Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 109: Australia 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
INDIA
- Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 110: India Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: India Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 112: India 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 113: India Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 114: India Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 115: India 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
SOUTH KOREA
- TABLE 116: South Korea Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 117: South Korea Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 118: South Korea 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 119: South Korea Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 120: South Korea Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 121: South Korea 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
- TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 123: Rest of Asia-Pacific Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 126: Rest of Asia-Pacific Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
LATIN AMERICA
- Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 128: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 129: Latin America Historic Review for Uterine Fibroid Treatment Devices by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 130: Latin America 15-Year Perspective for Uterine Fibroid Treatment Devices by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
- TABLE 131: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 132: Latin America Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 133: Latin America 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 134: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 135: Latin America Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 136: Latin America 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
ARGENTINA
- TABLE 137: Argentina Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 138: Argentina Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 139: Argentina 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 140: Argentina Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 141: Argentina Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 142: Argentina 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
BRAZIL
- TABLE 143: Brazil Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 144: Brazil Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 145: Brazil 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 146: Brazil Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 147: Brazil Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 148: Brazil 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
MEXICO
- TABLE 149: Mexico Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 150: Mexico Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 151: Mexico 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 152: Mexico Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 153: Mexico Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 154: Mexico 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
- TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 156: Rest of Latin America Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 157: Rest of Latin America 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 159: Rest of Latin America Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 160: Rest of Latin America 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
MIDDLE EAST
- Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 161: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 162: Middle East Historic Review for Uterine Fibroid Treatment Devices by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 163: Middle East 15-Year Perspective for Uterine Fibroid Treatment Devices by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
- TABLE 164: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 165: Middle East Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 166: Middle East 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 167: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 168: Middle East Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 169: Middle East 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
IRAN
- TABLE 170: Iran Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 171: Iran Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 172: Iran 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 173: Iran Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 174: Iran Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 175: Iran 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
ISRAEL
- TABLE 176: Israel Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 177: Israel Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 178: Israel 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 179: Israel Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 180: Israel Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 181: Israel 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
SAUDI ARABIA
- TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 183: Saudi Arabia Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 184: Saudi Arabia 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 186: Saudi Arabia Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 187: Saudi Arabia 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
- TABLE 188: UAE Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 189: UAE Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 190: UAE 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 191: UAE Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 192: UAE Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 193: UAE 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
- TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 195: Rest of Middle East Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 196: Rest of Middle East 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 198: Rest of Middle East Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 199: Rest of Middle East 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030
AFRICA
- Uterine Fibroid Treatment Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 200: Africa Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 201: Africa Historic Review for Uterine Fibroid Treatment Devices by Technology - Surgical and Ablation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 202: Africa 15-Year Perspective for Uterine Fibroid Treatment Devices by Technology - Percentage Breakdown of Value Sales for Surgical and Ablation for the Years 2015, 2025 & 2030
- TABLE 203: Africa Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 204: Africa Historic Review for Uterine Fibroid Treatment Devices by Mode of Treatment - Invasive, Minimally Invasive and Non-Invasive Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 205: Africa 15-Year Perspective for Uterine Fibroid Treatment Devices by Mode of Treatment - Percentage Breakdown of Value Sales for Invasive, Minimally Invasive and Non-Invasive for the Years 2015, 2025 & 2030